Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

被引:0
|
作者
Wu, Yuanlin [1 ]
Yu, Guangmao [1 ]
Jin, Ketao [2 ]
Qian, Jun [3 ]
机构
[1] Shaoxing Peoples Hosp, Dept Thorac Surg, Shaoxing, Zhejiang, Peoples R China
[2] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Dept Gastrointestinal Colorectal & Anal Surg, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Xinchang Peoples Hosp, Affiliated Xinchang Hosp, Dept Colorectal Surg, Xinchang, Zhejiang, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
non-small cell lung cancer; immunotherapy; combination therapy; cancer vaccines; tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-CHECKPOINT INHIBITOR; TYROSINE KINASE INHIBITORS; REGULATORY T-CELLS; PD-L1; EXPRESSION; ADVANCED NSCLC; OPEN-LABEL; PHASE-III; 1ST-LINE NIVOLUMAB; TARGETED THERAPIES;
D O I
10.3389/fimmu.2024.1349502
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made in recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, the mechanistic underpinnings, and the clinical evidence supporting their utilization is crucial in NSCLC therapy. Regarding the synergistic potential of combination immunotherapies, this study aims to provide insights to help the landscape of NSCLC treatment and improve clinical outcomes. In addition, this review article discusses the challenges and considerations of combination regimens, including toxicity management and patient selection.
引用
收藏
页数:31
相关论文
共 50 条
  • [41] Pemetrexed in the treatment of non-small cell lung cancer
    Shepherd, FA
    SEMINARS IN ONCOLOGY, 2002, 29 (06) : 43 - 48
  • [42] Advances in the treatment of non-small cell lung cancer
    Saijo, Nagahiro
    CANCER TREATMENT REVIEWS, 2008, 34 (06) : 521 - +
  • [43] Vaccines for the treatment of non-small cell lung cancer
    Leduc, C.
    Quoix, E.
    REVUE DES MALADIES RESPIRATOIRES, 2019, 36 (03) : 415 - 425
  • [44] Advances in the Treatment of Non-Small Cell Lung Cancer
    Horn, Leora
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (5.5): : 764 - 767
  • [45] Immunotherapy in the treatment of non-small cell lung cancer
    Sundar, Raghav
    Soong, Richie
    Cho, Byoung-Chul
    Brahmer, Julie R.
    Soo, Ross A.
    LUNG CANCER, 2014, 85 (02) : 101 - 109
  • [46] Vinorelbine in the treatment of non-small cell lung cancer
    Gridelli, C
    De Vivo, R
    CURRENT MEDICINAL CHEMISTRY, 2002, 9 (08) : 879 - 891
  • [47] Advances in treatment for non-small cell lung cancer
    Price, Katharine A.
    Jett, James R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (07) : 792 - 794
  • [48] Atezolizumab for the treatment of non-small cell lung cancer
    Santini, Fernando C.
    Rudin, Charles M.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (09) : 935 - 945
  • [49] Targeted Treatment for the Non-Small Cell Lung Cancer
    Komaki, R.
    RADIOTHERAPY AND ONCOLOGY, 2016, 118 : S59 - S60
  • [50] Trastuzumab in the treatment of non-small cell lung cancer
    Azzoli, CG
    Krug, LM
    Miller, VA
    Kris, MG
    Mass, R
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 59 - 65